Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of SYH2068 injection in adults with elevated lipoprotein(a)
CTR20262154Phase 2Active
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- Jul 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SYH2068 in hyperlipoproteinemia, sponsored by CSPC Zhongnuo Pharmaceutical. Started Jul 2026; status: active.
02
Drugs
SYH2068
03
Conditions
hyperlipoproteinemia
Beyond the preview
Go deeper on CTR20262154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262154.